Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab in Melanoma with >3 Brain Metastases
NCT03728465Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in melanoma, sponsored by University Hospital Tübingen. Started Apr 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03728465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728465.